Vitiligo is a chronic autoimmune disorder that causes the loss of skin pigmentation, resulting in white patches on the skin. While there is currently no cure for vitiligo, several upcoming, pipeline, and experimental treatments offer hope for improved management and repigmentation. This article explores the latest research and developments in vitiligo treatments, focusing on clinical trials, research papers, and expert opinions.
Clinical Trials for Vitiligo Treatments in the US
Several clinical trials are underway in the US, investigating new treatments for vitiligo. Some of the most promising trials include:
- A phase 3 trial investigates Afamelanotide (MC1R analog) in combination with narrow-band UVB phototherapy. Phase 2 studies demonstrated a higher repigmentation rate in this combination group when compared to phototherapy alone.1
- VYN201: This Phase 2b trial investigates VYN201, a novel BET inhibitor, for treating nonsegmental vitiligo. VYN201 is a topical gel that aims to provide significant benefits with low systemic exposure5.
- Oral JAK Inhibitors: Several oral JAK inhibitors, including baricitinib, upadacitinib, and povorcitinib, are being tested in Phase II trials. These oral medications offer a potential advantage over topical treatments by reaching a wider area of the skin, but may also have a greater risk of side effects1. Topical JAK inhibitors, on the other hand, offer more targeted treatment with potentially fewer side effects7.
- Pfizer’s Tranquillo Trial: This trial is exploring an oral JAK inhibitor (Ritlecitinib) specifically for non-segmental vitiligo, which is currently lacking approved oral treatment options. Participating in this trial will help researchers understand if a once-daily pill is effective in treating this condition8.
- Vitiligo Clinical Trials in Indiana: Ongoing clinical trials in Indiana are exploring potential vitiligo treatments, including a potential new drug for non-segmental vitiligo. These trials are contributing to the development of new drugs and therapies for vitiligo9.
Research Papers on Upcoming Vitiligo Treatments
Recent studies have explored various potential treatments for vitiligo, including:
- Silymarin “Milk Thistle” in Combination with Hair Follicle Transplantation: A 2024 study evaluated the effectiveness of oral silymarin, an immune system modulator, combined with hair follicle transplantation for treating refractory vitiligo. The study involved 20 participants, with 12 receiving the combination therapy and 10 receiving a placebo. Results showed significant repigmentation in the group receiving the combination therapy10.
- Prostaglandin Analogues and PDE Inhibitors: Studies indicate that prostaglandin analogues (PGAs) and phosphodiesterase inhibitors (PDEIs) show promise for vitiligo, either alone or in combination with other therapies. These treatments have shown better results than traditional options like topical steroids or phototherapy in some cases10.
- Piperine: Research suggests that piperine, a compound found in black pepper, can stimulate melanocyte growth and dendrite formation. Studies are ongoing to determine its efficacy as a vitiligo treatment4.
Experimental Vitiligo Treatments
In addition to clinical trials and research papers, several experimental treatments are being explored for vitiligo:
Immune System Modulation:
- Topical Ruxolitinib with UVB Irradiation and Prostaglandin Supplementation: This three-pronged approach, currently in pre-clinical testing, has shown promising results in mouse models. It combines existing immunosuppressant drugs with controlled UVB irradiation and prostaglandin supplementation11.
Cell Regeneration:
- Targeting the WNT Signaling Pathway: The WNT signaling pathway, which is repressed in depigmented skin, is being investigated as a potential target for vitiligo treatments21.
New Drugs and Therapies in Development for Vitiligo
The FDA recently approved Opzelura (ruxolitinib) cream as the first topical treatment for repigmentation in vitiligo patients. This is a significant milestone in vitiligo treatment, as it offers a new option for patients seeking to restore their skin pigmentation12.
Mechanism of Action of Opzelura
Opzelura is a JAK inhibitor that works by reducing inflammation and modulating the immune response. It specifically targets the JAK-STAT pathway, which plays a crucial role in the immune system’s attack on melanocytes (pigment-producing cells) in people with vitiligo. By inhibiting this pathway, Opzelura may help reduce melanocyte destruction and promote repigmentation over time14.
Other new therapies include:
- RECELL®: This one-time therapy uses the patient’s healthy cells to stimulate lasting repigmentation in stable vitiligo. The FDA recently granted breakthrough device approval for RECELL®. In this procedure, a small amount of the patient’s healthy skin is harvested, and the melanocytes are processed to create a solution of skin cells. This solution is then applied to the white patches of skin that have been prepared with laser ablation. Studies showed that more than a third of RECELL participants saw greater than 80% repigmentation 24 weeks after treatment, while over half of patients saw greater than 50% repigmentation over the same period. The hope is that RECELL will become a procedure that any dermatologist could perform with minimal training16.
Ongoing Research into the Causes of Vitiligo
While the exact cause of vitiligo remains unknown, ongoing research is exploring various factors that may contribute to the disease, including:
- Genetics: Studies suggest that approximately 30% of vitiligo cases are genetic. Several possible genetic mutations affect how melanocyte cells function17.
- Environmental Factors: Stress, exposure to ultraviolet radiation, and contact with certain chemicals may trigger vitiligo in predisposed individuals18.
Researchers face significant challenges in understanding the complex interplay of genetic and environmental factors that contribute to vitiligo. Unraveling the approximately 200 genes and various other factors involved requires extensive research and analysis20.
Conclusion
Vitiligo research is rapidly advancing, with several promising treatments in development. Clinical trials are investigating new drugs and therapies, while research papers are exploring the underlying causes of the disease. These advancements offer hope for improved management and repigmentation for people with vitiligo1. The development of new treatments like Opzelura and RECELL®, along with ongoing research into oral JAK inhibitors and other therapies, holds the potential to significantly improve the quality of life for individuals with vitiligo. These advancements may not only restore skin pigmentation but also alleviate the emotional and psychological impact of this condition. It is essential to consult with a dermatologist to discuss the latest treatment options and determine the best course of action for individual needs.
Works cited
2. FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology – PMC, accessed January 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9486756/
3. New and Upcoming Treatment for Vitiligo, Atopic Dermatitis, accessed January 13, 2025, https://www.ajmc.com/view/new-and-upcoming-treatment-for-vitiligo-atopic-dermatitis
4. Latest Vitiligo Research: Advancements and Discoveries, accessed January 13, 2025, https://vitiligosociety.org/research/
5. 2024 Vitiligo Breakthroughs – Dermatology Times, accessed January 13, 2025, https://www.dermatologytimes.com/view/2024-vitiligo-breakthroughs
6. Advancements in Vitiligo: 2024 and Beyond – Dermsquared, accessed January 13, 2025, https://dermsquared.com/videos/topical-conversations/advancements-in-vitiligo-2024-and-beyond
7. A New Hope for Repigmentation: JAK Inhibitors and Vitiligo – UMass Chan Medical School, accessed January 13, 2025, https://www.umassmed.edu/vitiligo/blog/blog-posts1/2024/06/a-new-hope-for-repigmentation-jak-inhibitors-and-vitiligo/
8. Nonsegmental Vitiligo Clinical Trial | Pfizer, accessed January 13, 2025, https://www.pfizerclinicaltrials.com/nct05583526-vitiligo-trial
9. Vitiligo Clinical Trials in Indiana | Non-Segmental Vitiligo, accessed January 13, 2025, https://dermatrials.medicine.iu.edu/paid-research-studies/vitiligo-clinical-trials
10. Vitiligo Treatment Research Roundup: July to September 2024 – SimcoDerm, accessed January 13, 2025, https://simcoderm.com/vitiligo-treatment-research-roundup-july-to-september-2024/
11. Light and labor-inducing molecule: a new treatment for vitiligo?, accessed January 13, 2025, https://www.vet.cornell.edu/about-us/news/20240201/light-and-labor-inducing-molecule-new-treatment-vitiligo
12. Opzelura (ruxolitinib) for the Treatment of Vitiligo, US – Clinical Trials Arena, accessed January 13, 2025, https://www.clinicaltrialsarena.com/projects/opzelura-ruxolitinib-treatment-vitiligo-us/
13. FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older, accessed January 13, 2025, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older
14. Recently FDA-approved drug: A new hope for vitiligo patients? – PMC, accessed January 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9577636/
15. What is OPZELURA® (ruxolitinib) for Nonsegmental Vitiligo, accessed January 13, 2025, https://www.opzelura.com/vitiligo/what-is-opzelura
16. Breakthroughs offer hope for vitiligo patients – UCI Health, accessed January 13, 2025, https://www.ucihealth.org/blog/2023/06/vitiligo-breakthroughs
17. Vitiligo: Types, Symptoms, Causes, Treatment & Recovery – Cleveland Clinic, accessed January 13, 2025, https://my.clevelandclinic.org/health/diseases/12419-vitiligo
18. Vitiligo – Genetics – MedlinePlus, accessed January 13, 2025, https://medlineplus.gov/genetics/condition/vitiligo/
19. Vitiligo Overview: Types, Causes, Symptoms, and Treatment – Pfizer, accessed January 13, 2025, https://www.pfizer.com/disease-and-conditions/vitiligo
20. Clinical study aims to identify early molecular and biological signatures of vitiligo, accessed January 13, 2025, https://www.umassmed.edu/news/news-archives/2023/06/clinical-study-aims-to-identify-early-molecular-and-biological-signatures-of-vitiligo/
21. The possible role of Wnt/β-catenin signalling in vitiligo treatment. https://pubmed.ncbi.nlm.nih.gov/36912722/
Zehn Skin and Health 
Leave a comment